Abstract |
Development of a vaccine against Epstein-Barr virus (EBV) is constrained by the latency phenotypes adopted by different EBV-associated diseases. Over the last few years an immense body of information on the pattern of viral gene expression in EBV-associated diseases and the role of cytotoxic T cells in the control of these diseases has accumulated. It would seem reasonable to suggest that emerging technologies are at a level where vaccine trials aimed at controlling infectious mononucleosis, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma and Hodgkin's disease are justified. On the other hand, a more cautious approach may be required for the development of vaccines or immunotherapeutic strategies against Burkitt's lymphoma.
|
Authors | R Khanna, D J Moss, S R Burrows |
Journal | Immunological reviews
(Immunol Rev)
Vol. 170
Pg. 49-64
(Aug 1999)
ISSN: 0105-2896 [Print] England |
PMID | 10566141
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antigens, Viral
- Viral Vaccines
|
Topics |
- Animals
- Antigens, Viral
- Burkitt Lymphoma
(immunology, therapy)
- Disease Models, Animal
- Epstein-Barr Virus Infections
(immunology, prevention & control, virology)
- Herpesvirus 4, Human
(genetics, immunology, pathogenicity)
- Humans
- Immunotherapy
- Infant, Newborn
- Infectious Mononucleosis
(immunology, prevention & control)
- Mice
- Phenotype
- Primates
- T-Lymphocytes, Cytotoxic
(immunology)
- Viral Vaccines
(pharmacology)
|